Loading organizations...
Key people at M. H. Carnegie & Co..
M. H. Carnegie & Co. was founded in 2011 by Mark Carnegie (Founder).
M.H. Carnegie & Co. is an Australian alternative asset manager that deploys capital across a diverse range of investment platforms. The firm specializes in venture capital, private equity, and real estate, employing a strategy focused on building robust platform businesses. This approach integrates deep financial expertise with the specific sector knowledge and extensive networks of industry leaders, aiming to generate substantial value for its investments.
The firm was founded in 2010 by Mark Carnegie, a figure known for his entrepreneurial endeavors. Carnegie’s vision for M.H. Carnegie & Co. stemmed from the insight that significant value creation in alternative assets could be achieved by fostering strong partnerships with experienced professionals, enabling the development of market-leading companies within various sectors. This strategic foundation underpins their investment philosophy.
M.H. Carnegie & Co. serves a client base of investors seeking exposure to expertly managed alternative assets. Its long-term vision centers on continuously identifying and cultivating promising platform businesses across sectors such as medical devices, real estate, and consumer goods. The firm is committed to driving growth and delivering attractive returns through its disciplined investment methodology and collaborative engagement with portfolio companies.
M. H. Carnegie & Co. was founded in 2011 by Mark Carnegie (Founder).
Key people at M. H. Carnegie & Co..
M. H. Carnegie & Co. has 2 tracked investments across 2 companies. The latest tracked deal is $4.0M Seed in DigiBuild in July 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 25, 2022 | DigiBuild | $4.0M Seed | — | Blue Field Capital, Build Technologies, Cathexis Ventures, Chain Reaction Boston, Draper Associates, Harvard University, Orange DAO, Picus Capital, Y Combinator |
| Jul 1, 2017 | Simplify Medical | $21.0M Series B | Fouad Azzam, Ph.D. | EQT Life Sciences, VantagePoint Capital Partners, Sectoral Asset Management |